Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 701–800 of 1,001
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
Vishram‐Nielsen, J. K. K., Tomasoni, D., Gustafsson, F., & Metra, M. (2022) · Drugs · doi:10.1007/s40265-021-01666-z · Cited by 19
Evaluation of the HFA-PEFF Score: Results from the Prospective DIAST-CHF Cohort
Hashemi, D., Mende, M., Trippel, T. D., Petutschnigg, J., Hasenfuss, G. P., Nolte, K., Herrmann‐Lingen, C., Feuerstein, A., Langhammer, R., Tschöpe, C., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14131 · Cited by 18
Review: Heart failure with preserved ejection fraction in African Americans.
Shah, S. (2012) · PubMed · Cited by 18
Reed, B. N., Rodgers, J. E., & Sueta, C. A. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.07.005 · Cited by 20
SEX, SCIENCE, AND PSEUDOSCIENCE IN THE PUBLIC SPHERE
Lancaster, R. N. (2006) · Identities · doi:10.1080/10702890500535707 · Cited by 18
“Can there be special drugs for African-Americans (or whites), as a recent study has claimed (Taylor et al. 2004)?”
BackgroundCurrent management of pediatric dilated cardiomyopathy
Silva, J. N. A., & Canter, C. E. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328335b220 · Cited by 20
Khalil, C. A., Sulaiman, K., Mahfoud, Z. R., Singh, R., Asaad, N., AlHabib, K. F., Alsheikh-Ali, A. A. A., Al‐Jarallah, M., Bulbanat, B., Almahmeed, W. A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014915 · Cited by 19
Tillman, F., Kim, J., Makhlouf, T. K., & Osae, L. (2019) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944719840192 · Cited by 18
Tam, S. W., Sabolinski, M. L., Worcel, M., Packer, M., & Cohn, J. N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746100-00006 · Cited by 18
Self-citationRosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J. M., Izzo, J. L., Kaplan, N. M., O’Connor, C. M., O’Gara, P. T., & Oparil, S. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.183885 · Cited by 20
BiDil: From Another Vantage Point
Puckrein, G. A. (2006) · Health Affairs · doi:10.1377/hlthaff.25.w368 · Cited by 18
“The group receiving BiDil showed a 43 percent improvement in survival.(15) Sankar, Kahn, and others object to A-HeFT’s design, particularly the absence of non–African American subjects.”
BackgroundWhat's right (and wrong) with racially stratified research and therapies.
Sade, R. M. (2007) · PubMed · Cited by 17
Heterogeneity in treatment effects across diverse populations
Nugent, B. M., Madabushi, R., Buch, B., Peiris, V., Crentsil, V., Miller, V. M., Bull, J. C., & Jenkins, M. (2021) · Pharmaceutical Statistics · doi:10.1002/pst.2161 · Cited by 17
“This disparity in heart failure outcomes is likely due to both sociocultural differences in risk factors and health care access as well as potential physiological differences such as lower nitric oxide bioavailability.(21) Isosorbide/hydralazine combination therapy was approved to treat congestive heart failure in Afr…”
BackgroundThe Importance of Cultural Awareness in the Management of Heart Failure: A Narrative Review
Beattie, J. M., Castiello, T., & Jaarsma, T. (2024) · Vascular Health and Risk Management · doi:10.2147/vhrm.s392636 · Cited by 20
“…on from the A-HeFT study that showed significant benefits for this patient cohort in improved quality of life and reduced rates of hospitalization and death, 37 this drug combination is still under prescribed in the US, and in the treatment of HFrEF patients of African origin living in Europe.”
BackgroundSystolic heart failure in the elderly: optimizing medical management
Man, J. P., & Jugdutt, B. I. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9282-y · Cited by 17
Nitrates and Other Nitric Oxide Donors in Cardiology - Current Positioning and Perspectives
Bellisarii, F. I., Radico, F., Muscente, F., Horowitz, J. D., & Caterina, R. D. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6354-0 · Cited by 23
“01), the incidence of a first hospitalization for heart failure by 33%, and improves quality of life compared with placebo [47].”
BackgroundYang, S., Starks, M. A., Hernandez, A. F., Turner, E. L., Califf, R. M., O’Connor, C. M., Mentz, R. J., & Choudhury, K. R. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.04.016 · Cited by 19
McGuinty, C., Leong, D., Weiss, A. J., MacIver, J., Kaya, E., Hurlburt, L., Billia, F., Ross, H. J., & Wentlandt, K. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.12.357 · Cited by 21
Relationship Between Dietary Magnesium Intake and Incident Heart Failure Among Older Women: The WHI
Wu, W., Huang, M., Taveira, T. H., Roberts, M. B., Martin, L. W., Wellenius, G. A., Johnson, K., Manson, J. E., Liu, S., & Eaton, C. B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013570 · Cited by 17
de Vries, A. E., de Jong, R. M., van der Wal, M. H. L., Jaarsma, T., van Dijk, R. B., & Hillege, H. L. (2011) · BMC Health Services Research · doi:10.1186/1472-6963-11-167 · Cited by 17
“These figures are based on a publication [37] in which the effect of the combination of isosorbidedinitrate and hydralazin was investigated in patient with HF.”
BackgroundAsymmetric Dimethylarginine, Race, and Mortality in Hemodialysis Patients
Drew, D. A., Tighiouart, H., Scott, T. M., Kantor, A., Fan, L., Artusi, C., Plebani, M., Weiner, D. E., & Sarnak, M. J. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00770114 · Cited by 17
Ilksoy, N., Hoffman, M., Moore, R. H., Easley, K. A., & Jacobson, T. A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.066 · Cited by 17
Reversing chronic remodeling in heart failure
Mudd, J. O., & Kass, D. A. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.3.585 · Cited by 22
Emerging drugs for the treatment of angina pectoris
Chong, C., Ong, G. J., & Horowitz, J. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241231 · Cited by 17
“enon of nitrate tolerance (loss of effect during prolonged use) [8] and also shown to reduce mortality in patients with associated heart failure [9,10].”
BackgroundManagement of advanced heart failure: a review
Kalmanovich, E., Audurier, Y., Akodad, M., Mourad, M., Battistella, P., Agullo, A., Gaudard, P., Colson, P. H., Rouvière, P., Albat, B., et al. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1530112 · Cited by 18
Sex and Gender-Related Issues in Heart Failure
Romiti, G. F., Recchia, F., Zito, A., Visioli, G., Basili, S., & Raparelli, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.005 · Cited by 16
Pathway for the Management of Acute Heart Failure
Herzog, E., Varley, C., & Kukin, M. L. (2005) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/01.hpc.0000154606.55424.fc · Cited by 18
Racial medicine: here to stay?
Weigmann, K. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400654 · Cited by 17
“However, most scientists agree that race makes a bad scientific concept (Rotimi, 2004; Tishkoff & Kidd, 2004; Wilson et al, 2001).”
BackgroundDrug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure
Howard, P. A., Cheng, J. W. M., Crouch, M. A., Colucci, V. J., Kalus, J. S., Spinler, S. A., & Munger, M. A. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h059 · Cited by 19
Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz
Böhm, M., Werner, N., & Kindermann, M. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-2008-9 · Cited by 17
Inducible Nitric Oxide Synthase in Severe Human Heart Failure⁎
Starling, R. C. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.021 · Cited by 17
Siddiqui, W. J., Aggarwal, S., Rafique, M., Singh, S., Kutalek, S., & Eisen, H. J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9671-6 · Cited by 16
“ICD implantation has been a revolutionary advancement in the treatment of heart failure with reduced ejection fraction secondary to both ICM and NICM in the past decade [30].”
Branzi, G., Malfatto, G., Villani, A., Ciambellotti, F., Revera, M., Giglio, A., Rosa, F. D., Facchini, M., & Parati, G. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32833832f6 · Cited by 16
Maglo, K. N., Rubinstein, J., Huang, B., & Ittenbach, R. F. (2014) · AJOB Empirical Bioethics · doi:10.1080/23294515.2014.907371 · Cited by 16
“Results of the trial demonstrated that a fixed-dose combination of two generic drugs, isosorbide dinitrate and hydralazine hydrochloride, reduced first hospitalization by 33% and increased survival rate by 43% in self-identified African American patients with congestive heart failure (Taylor et al. 2004).”
BackgroundMethodInfluentialPharmacological interventions for heart failure in people with chronic kidney disease
Ravani, P., Quinn, R. R., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466 · Cited by 16
Racial Difference in Efficacy of Golimumab in Ulcerative Colitis
Greywoode, R., Petralia, F., Ullman, T. A., Colombel, J., & Ungaro, R. C. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac161 · Cited by 16
Heart Failure: Who We Treat Versus Who We Study
Miller, L. W. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.10.005 · Cited by 18
Frontiers of Therapy for Patients With Heart Failure
Liu, S. S., Monti, J., Kargbo, H. M., Athar, M. W., & Parakh, K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.033 · Cited by 20
Dental care for patients with heart failure
Herman, W. W., & Ferguson, H. W. (2010) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2010.0282 · Cited by 16
The Three-Decade Long Journey in Heart Failure Drug Development
Lewis, K. S., Butler, J., Bauersachs, J. K., & Sandner, P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_101 · Cited by 18
Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials
Singh, P., Vijayakumar, S., Kalogeroupoulos, A., & Butler, J. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0383-y · Cited by 16
Democratizing Strategies for Industry-Funded Medical Research: A Cautionary Tale
Pinto, M. F. (2018) · Philosophy of Science · doi:10.1086/699720 · Cited by 18
Kemp‐Harper, B. K., Velagic, A., Paolocci, N., Horowitz, J. D., & Ritchie, R. H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_389 · Cited by 17
Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
Becher, M. U., Balata, M., Hesse, M., Draht, F., Zachoval, C., Weltermann, B., Westenfeld, R., Neukirchen, M., Pfister, R., Standl, T. G., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01903-1 · Cited by 19
Aldehydes and Cardiovascular Disease
Conklin, D. J., & Bhatnagar, A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00723-5 · Cited by 17
Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction
Heart Failure Society of America (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.11.012 · Cited by 17
Management of hypertension in chronic heart failure
Manickavasagam, S., Merla, R., Koerner, M. M., Fujise, K., Kunapuli, S., Rosanio, S., & Barbagelata, A. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.8 · Cited by 16
Racial Differences in Heart Failure Therapeutics
Ishizawar, D. C., & Yancy, C. W. (2009) · Heart Failure Clinics · doi:10.1016/j.hfc.2009.08.006 · Cited by 16
Self-citationJolley, S. E., Hough, C. L., Clermont, G., Hayden, D., Hou, S., Schoenfeld, D., Smith, N. L., Thompson, B., Bernard, G. R., & Angus, D. C. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201611-906oc · Cited by 16
Wu, A. H. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201806050 · Cited by 18
Cohn, J. N. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.063 · Cited by 16
Self-citationMaterializing Hope: Racial Pharmaceuticals, Suffering Bodies, and Biological Citizenship
Inda, J. X. (2011) · Palgrave Macmillan US eBooks · doi:10.1057/9780230119536_4 · Cited by 15
Wang, S., Peng, H., & Hung, H. M. J. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.02.004 · Cited by 15
Tang, H., Germinal, K., Milfort, A., Chen, W., Chang, S., Huang, W., Li, Y., Lu, Y., Ahmed, M. M., Kimmel, S. E., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04339-3 · Cited by 16
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 16
Sliwa, K. S., Damasceno, A. A. M., Davison, B. A., Mayosi, B. M., Sani, M. U., Ogah, O. S., Mondo, C. K., Ojji, D. B., Dzudié, A., Kouam, C. K., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.581 · Cited by 15
Advanced heart failure - a review
Kępińska, K., Adamczak, D., & Kałużna‐Oleksy, M. (2019) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/103669 · Cited by 16
Liu, J., Tang, M., Li, T., Su, Z., Zhu, Z., Dou, C., Liu, Y., Pei, H., Yang, J., Ye, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.811682 · Cited by 16
“…RESEARCH published: 21 February 2022 doi: 10.3389/fphar.2022.811682 HF cases are associated with obstructive coronary artery disease (CAD) (Abraham et al., 2002; Bristow et al., 2004; Taylor et al., 2004; Bardy et al., 2005; Cleland et al., 2005; Elgendy et al., 2019; Heallen et al., 2019).”
BackgroundInfluentialToward Inclusivity in Preclinical Drug Development: A Proposition to Start with Intestinal Organoids
Co, J. Y., Klein, J. A., Kang, S., & Homan, K. A. (2023) · Advanced Biology · doi:10.1002/adbi.202200333 · Cited by 15
Cardiovascular disease disparities: Racial/ethnic factors and potential solutions
Ferdinand, K. C., & Ferdinand, D. P. (2009) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-009-0030-y · Cited by 15
Self-citationLiberts, E. A., Willoughby, S. R., Kennedy, J. A., & Horowitz, J. D. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.01.001 · Cited by 15
Advances in Pharmacologic Modulation of Nitric Oxide in Hypertension
Mizuno, Y., Jacob, R. F., & Mason, R. P. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0142-5 · Cited by 18
“In the A-HeFT study, the concomitant administration of isosorbide dinitrate and hydralazine, in addition to standard background therapy for mild to severe heart failure, was shown to reduce the overall mortality rate by 43% among African Americans with advanced disease [ 47 ].”
BackgroundPharmacogenomic technologies: a necessary "luxury" for better global public health?
Olivier, C., & Williams–Jones, B. (2011) · Globalization and Health · doi:10.1186/1744-8603-7-30 · Cited by 15
“This drug was shown to reduce mortality by 43% and hospitalisations by 39% in African-Americans, but showed no specific increase in efficiency for other racial groups [61].”
BackgroundChan, M. C. Y., & Tsuyuki, R. T. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32835dd0e9 · Cited by 19
Drug therapies in chronic heart failure: a focus on reduced ejection fraction
Bolam, H., Morton, G., & Kalra, P. R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-138 · Cited by 15
Carmody, M. S., & Anderson, J. R. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000250840.15645.fb · Cited by 15
“The African-American Heart Failure Trial (A-HeFT) addressed the issue of race-based therapeutics by investigating the use of BiDil added to conventional therapy in a population that self-identified as being black.(45) A-HeFT was a double-blind, placebo-controlled, multicenter trial of 1050 patients randomized to recei…”
BackgroundMethodChan, J. D., Rea, T. D., Smith, N. L., Siscovick, D. S., Heckbert, S. R., Lumley, T., Chaves, P. H. M., Furberg, C. D., Kuller, L. H., & Psaty, B. M. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.022 · Cited by 15
Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure
Echols, M. R., & Yancy, C. W. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.4.423 · Cited by 15
“The A-HeFT study randomized 1050 African American patients with moderate to severe systolic heart failure (NYHA III and IV) to fixed-dose ISDN-HYD therapy or placebo (Taylor 2003, 2005; Taylor et al 2004).”
MethodSelf-citationAcute Decompensated Heart Failure
Hammond, D. A., Smith, M. N., Lee, K. C., Honein, D., & Miller, A. D. (2016) · Journal of Intensive Care Medicine · doi:10.1177/0885066616669494 · Cited by 17
El-Zein, R. S., Mohammed, M., Nguyen, D. D., Hill, C. L., Thomas, L. E., Nassif, M. E., DeVore, A. D., Albert, N. M., Butler, J., Patterson, J. H., et al. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.123.010211 · Cited by 17
Role of the Acute Care Nurse in Managing Patients With Heart Failure Using Evidence-Based Care
Paul, S. C., & Hice, A. (2014) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000036 · Cited by 14
Peripheral tissue oxygenation improves during ED treatment of acute heart failure
Hogan, C. J., Ward, K. R., Kontos, M. C., Thacker, L. R., & Pittman, R. N. (2011) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2010.10.019 · Cited by 15
“Our population had a high proportion of African Americans, who may respond differently to HF therapy [21,22].”
BackgroundHeart Failure. Are Women Different?
Leiro, M. G. C., & Martín, M. J. P. (2006) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(07)60031-0 · Cited by 18
Wang, Y., Nguyen, D. T., Yang, G., Anesi, J., Chai, Z., Charchar, F. J., & Golledge, J. (2020) · Assay and Drug Development Technologies · doi:10.1089/adt.2020.1004 · Cited by 14
Felker, G. M., Solomon, S. D., McMurray, J. J. V., Cleland, J. G. F., Abbasi, S. A., Malik, F. I., Zhang, H., Globe, G. A., Teerlink, J. R., & for the COSMIC-HF Investigators (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007814 · Cited by 17
Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction
Kim, E.-S., Youn, J., & Baek, S. H. (2020) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2020.2.e17 · Cited by 16
Mathews, L., Ding, N., Sang, Y., Loehr, L. R., Shin, J.-I., Punjabi, N. M., Bertoni, A. G., Crews, D. C., Rosamond, W. D., Coresh, J., et al. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01202-5 · Cited by 14
Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
Falco, L., Brescia, B., Catapano, D., Martucci, M. L., Valente, F., Gravino, R., Contaldi, C., Pacileo, G., & Masarone, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10090388 · Cited by 17
“Although previous attempts at targeting NO gave conflicting results [50–53], veri-ciguat successfully leverages the NO-sGC-cGMP pathway, finally translating a well-known biochemical rationale to improved clinical outcomes.”
ResultStrategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure
Psotka, M. A., & Teerlink, J. R. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.04.005 · Cited by 14
“Only the combination of vasodilators and diuretics reduced in-hospital mortality in the ALARM-HF registry, and the combination of isosorbide dinitrate with hydralazine decreased readmissions and mortality solely in self-described African Americans.(89,90) The unproductive results with decongestive therapies may altern…”
BackgroundDiagnosis and Management of Heart Failure in the Outpatient Setting
Wilbur, J., & James, P. A. (2005) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2005.09.005 · Cited by 17
The Baroreceptor as a Therapeutic Target for Heart Failure
Gronda, E., Lovett, E. G., Tarascio, M., Georgakopoulos, D., Grassi, G. M., & Vanoli, E. (2014) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-014-9546-8 · Cited by 14
“Chronic use in combination with hydralazine is supported by positive results in one cohort of African Americans [8], but evidence is lacking for chronic benefit in general HF populations.”
ResultManagement of End-Stage Heart Failure
Murthy, S., & Lipman, H. I. (2011) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2011.03.007 · Cited by 14
Hydralazine Associated Pauci-Immune Glomerulonephritis
Suneja, M., Baiswar, S., & Vogelgesang, S. A. (2014) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000049 · Cited by 14
“Because of its vasodilatory properties, it has also been used to manage heart failure in patients who cannot tolerate either angiotensin-converting enzyme inhibitors or angiotensinreceptor blockers.(2,3) It has many well-known adverse effects, including a set of chemically induced autoimmune phenomenon.”
MethodNitric Oxide Regulation of Cardiovascular Physiology and Pathophysiology
Dulce, R. A., Kulandavelu, S., Schulman, I. H., Fritsch, J., & Hare, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804273-1.00024-7 · Cited by 18
Cultural Diversity, Health Care Disparities, and Cultural Competency in American Medicine
Williams, R. A. (2007) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-200700001-00013 · Cited by 14
Race Does not Explain Genetic Heterogeneity in Pharmacogenomic Pathways
Revollo, J. Y., Auman, J. T., & McLeod, H. L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1639 · Cited by 14
“BiDil, a combination of hydralazine and isosorbide dinitrate, was approved for treating heart failure in AfricanAmerican patients, after results from the African-American Heart Failure Trial (A-HeFT) supported clinical benefit from the drug [10,101].”
ResultKreatsoulas, C., & Anand, S. S. (2009) · Vascular Medicine · doi:10.1177/1358863x09107006 · Cited by 14
Diagnosis and Management of Acute Heart Failure
Parks, K. A., Januzzi, J. L., & Januzzi, J. L. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4483-0_14 · Cited by 14
Kahn, J. (2006) · Nature Biotechnology · doi:10.1038/nbt1106-1349 · Cited by 14
Efficacy and Safety in Clinical Trials in Cardiovascular Disease
Cohn, J. N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.083 · Cited by 14
Self-citationIlksoy, N., Moore, R. H., Easley, K. A., & Jacobson, T. A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.116 · Cited by 14
Lee, M.-J., Han, J., Lee, J., Oh, J. Y., Kim, J. S., Gwak, H. S., & Choi, K. H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205624 · Cited by 13
“Another example of a drug requiring an ethnicity-based treatment strategy is the antihypertensive combination regimen of isosorbide dinitrate and hydralazine, which has been proven to be effective only in African Americans in clinical trials and was approved by FDA for use only in this population (Taylor et al., 2004).”
BackgroundSummary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines
Badger, S., McVeigh, J., & Indraratna, P. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00328-3 · Cited by 14
“…V-HeFT I and A-HeFT, have shown the addition of hydralazine and isosorbide dinitrate to guideline directed medical therapy (GDMT) leads to reduced morbidity and HF hospitalizations, as well as improvement of symptoms in self-identified black patients with HFrEF and NYHA class III-IV [26, 27].”
BackgroundRagab, M. S., Hameed, R. M. A., Shoukry, M. M., Roushdy, S. E., Mohammed, H. A., Shohdy, V. A., Sharawy, G. K., Elsayed, E. A., Ragab, F. M., Gamaleldin, Z. H., et al. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.113518 · Cited by 13
Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Case-Based Narrative Review
Javaid, A., Hariri, E. H., Özkan, B., Lang, K., Khan, S. S., Rangaswami, J., Stone, N. J., Blumenthal, R. S., & Ndumele, C. E. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100089 · Cited by 15
“28 He has moderate-risk CKD based on his eGFR and needs an assessment of UACR, when in steady state in the ambulatory setting, for further characterization and risk stratification of CKD risk.”
Breakthrough in heart failure with preserved ejection fraction: are we there yet?
Lim, S. L., & Lam, C. S. P. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.31.1.1 · Cited by 15
“The benefits of organic nitrates were largely demonstrated in HFREF patients, with improvements in mortality, HF hospitalizations and LV function [86,87].”
BackgroundA new class of drugs for systolic heart failure: The PARADIGM-HF study
Sabe, M., Jacob, M. S., & Taylor, D. O. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14163 · Cited by 13
Adesunloye, B. A., Valadri, R., Mbaezue, N., & Onwuanyi, A. (2012) · Cardiology Research and Practice · doi:10.1155/2012/306852 · Cited by 13
“Medical therapy in CHF escalates starting with angiotensin converting enzyme inhibitors [31], and Beta Blockers [32, 33] at NYHA class I and II, to Aldactone [34, 35], bidil [36], and inotropic therapy [37] as the FL deteriorates to NYHA class III and IV.”
MethodNitric Oxide Modulation as a Therapeutic Strategy in Heart Failure
Taylor, A. L. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2011.11.002 · Cited by 15
“An important treatment effect of fixed-dose ISDN/HYD was a significant decrease of 2 to 5 mm Hg in systolic blood pressure and a 2- to 4mm Hg reduction in diastolic blood pressure.(78,84) However, beneficial effects of fixed-dose ISDN/ HYD were similar in patients with blood pressures above and below the group median…”
BackgroundResultSelf-citationNitrates as adjunct hypertensive treatment
Stokes, G. S. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0042-7 · Cited by 13
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.